Kringle advances HGF therapy for renal failure
This article was originally published in Scrip
The Japanese bioventure Kringle Pharma has filed a US IND to begin clinical trials with a recombinant hepatocyte growth factor for the treatment of acute renal failure (ARF). The disorder, which is associated with a range of conditions including shock, has a mortality rate of around 50% and is now treated only symptomatically, Kringle notes. HGF is under-expressed in the condition, which affects around 700,000 people in the US, and studies suggest that administration of additional quantities aids the regeneration of renal function, the Osaka-based firm said. It has already partnered with the Swedish company Tripep to develop HGF for chronic leg wounds.